Lexicon Pharma (LXRX) Misses Q1 EPS by 4c

Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.34), $0.04 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $12.5 million versus the consensus estimate of $11.11 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c